NCT02906332 · OUTCOME

Comparison in Bone Marrow Aspirates of the Extent of Pre-pembrolizumab (MK-3475), Lenalidomide and Dexamethasone PD-L1 Expression and Change From Baseline PD-L1 Expression in Responders Versus Non-responders

Pembrolizumab + Lenalidomide Post Autologous Stem Cell Transplant (ASCT) in High-risk Multiple Myeloma (MM) · Source last updated 2023-08-22

This outcome was registered, but no numerical results were posted in the captured record.

Measure: Not reported
Unit: Not reported
Interval / dispersion: Not reported
Time frame: Bone marrow aspirate specimens will be obtained at screening and at week 15 (completion of cycle 4).

What was measured

Comparison of change from baseline in bone marrow aspirate/biopsy PD-L1 expression between responders with longer duration of response and non-responders or responders with a short duration of response will be performed using mixed regression analysis. Longitudinal analysis of bone marrow aspirate/biopsy PD-L1 expression over time will be examined using mixed model repeated measure design with levels observed serially over time and response type (long responders vs short responders/non-response) as a fixed variable.

Groups in this outcome

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields

denom Units Selected: Participants
description: Comparison of change from baseline in bone marrow aspirate/biopsy PD-L1 expression between responders with longer duration of response and non-responders or responders with a short duration of response will be performed using mixed regression analysis. Longitudinal analysis of bone marrow aspirate/biopsy PD-L1 expression over time will be examined using mixed model repeated measure design with levels observed serially over time and response type (long responders vs short responders/non-response) as a fixed variable.
reporting Status: NOT_POSTED
time Frame: Bone marrow aspirate specimens will be obtained at screening and at week 15 (completion of cycle 4).
title: Comparison in Bone Marrow Aspirates of the Extent of Pre-pembrolizumab (MK-3475), Lenalidomide and Dexamethasone PD-L1 Expression and Change From Baseline PD-L1 Expression in Responders Versus Non-responders
type: OTHER_PRE_SPECIFIED

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice